nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluticasone Propionate—PLA2G4A—Epirubicin—urinary bladder cancer	0.464	0.805	CbGbCtD
Fluticasone Propionate—CYP3A4—Thiotepa—urinary bladder cancer	0.0522	0.0907	CbGbCtD
Fluticasone Propionate—CYP3A5—Etoposide—urinary bladder cancer	0.0363	0.063	CbGbCtD
Fluticasone Propionate—CYP3A4—Etoposide—urinary bladder cancer	0.0142	0.0246	CbGbCtD
Fluticasone Propionate—CYP3A4—Doxorubicin—urinary bladder cancer	0.00966	0.0168	CbGbCtD
Fluticasone Propionate—NR3C1—urine—urinary bladder cancer	0.00509	0.0615	CbGeAlD
Fluticasone Propionate—PLA2G4A—Raltitrexed—Methotrexate—urinary bladder cancer	0.00507	1	CbGdCrCtD
Fluticasone Propionate—PLA2G4A—prostate gland—urinary bladder cancer	0.00419	0.0506	CbGeAlD
Fluticasone Propionate—CYP3A4—urine—urinary bladder cancer	0.00385	0.0465	CbGeAlD
Fluticasone Propionate—PLA2G4A—seminal vesicle—urinary bladder cancer	0.00354	0.0428	CbGeAlD
Fluticasone Propionate—NR3C2—prostate gland—urinary bladder cancer	0.00341	0.0412	CbGeAlD
Fluticasone Propionate—PGR—prostate gland—urinary bladder cancer	0.00317	0.0383	CbGeAlD
Fluticasone Propionate—PLA2G4A—smooth muscle tissue—urinary bladder cancer	0.00297	0.0358	CbGeAlD
Fluticasone Propionate—NR3C2—seminal vesicle—urinary bladder cancer	0.00288	0.0348	CbGeAlD
Fluticasone Propionate—PLA2G4A—renal system—urinary bladder cancer	0.00285	0.0345	CbGeAlD
Fluticasone Propionate—SERPINA6—renal system—urinary bladder cancer	0.00284	0.0344	CbGeAlD
Fluticasone Propionate—PLA2G4A—urethra—urinary bladder cancer	0.0028	0.0339	CbGeAlD
Fluticasone Propionate—NR3C2—smooth muscle tissue—urinary bladder cancer	0.00241	0.0292	CbGeAlD
Fluticasone Propionate—PGR—epithelium—urinary bladder cancer	0.00233	0.0281	CbGeAlD
Fluticasone Propionate—NR3C2—renal system—urinary bladder cancer	0.00232	0.0281	CbGeAlD
Fluticasone Propionate—PLA2G4A—female reproductive system—urinary bladder cancer	0.00229	0.0276	CbGeAlD
Fluticasone Propionate—NR3C2—urethra—urinary bladder cancer	0.00228	0.0276	CbGeAlD
Fluticasone Propionate—SERPINA6—female reproductive system—urinary bladder cancer	0.00228	0.0275	CbGeAlD
Fluticasone Propionate—PGR—smooth muscle tissue—urinary bladder cancer	0.00224	0.0271	CbGeAlD
Fluticasone Propionate—PLA2G4A—vagina—urinary bladder cancer	0.00207	0.025	CbGeAlD
Fluticasone Propionate—NR3C2—female reproductive system—urinary bladder cancer	0.00186	0.0225	CbGeAlD
Fluticasone Propionate—CYP3A5—prostate gland—urinary bladder cancer	0.00184	0.0223	CbGeAlD
Fluticasone Propionate—NR3C1—prostate gland—urinary bladder cancer	0.00183	0.0221	CbGeAlD
Fluticasone Propionate—PGR—female reproductive system—urinary bladder cancer	0.00173	0.0209	CbGeAlD
Fluticasone Propionate—NR3C2—vagina—urinary bladder cancer	0.00168	0.0203	CbGeAlD
Fluticasone Propionate—PGR—vagina—urinary bladder cancer	0.00156	0.0189	CbGeAlD
Fluticasone Propionate—NR3C1—seminal vesicle—urinary bladder cancer	0.00155	0.0187	CbGeAlD
Fluticasone Propionate—NR3C1—epithelium—urinary bladder cancer	0.00134	0.0162	CbGeAlD
Fluticasone Propionate—PLA2G4A—lymph node—urinary bladder cancer	0.00134	0.0162	CbGeAlD
Fluticasone Propionate—NR3C1—smooth muscle tissue—urinary bladder cancer	0.00129	0.0156	CbGeAlD
Fluticasone Propionate—CYP3A5—renal system—urinary bladder cancer	0.00125	0.0152	CbGeAlD
Fluticasone Propionate—NR3C1—renal system—urinary bladder cancer	0.00125	0.0151	CbGeAlD
Fluticasone Propionate—NR3C1—urethra—urinary bladder cancer	0.00122	0.0148	CbGeAlD
Fluticasone Propionate—NR3C2—lymph node—urinary bladder cancer	0.00109	0.0131	CbGeAlD
Fluticasone Propionate—PGR—lymph node—urinary bladder cancer	0.00101	0.0122	CbGeAlD
Fluticasone Propionate—NR3C1—female reproductive system—urinary bladder cancer	0.000997	0.0121	CbGeAlD
Fluticasone Propionate—CYP3A4—renal system—urinary bladder cancer	0.000942	0.0114	CbGeAlD
Fluticasone Propionate—CYP3A5—vagina—urinary bladder cancer	0.000909	0.011	CbGeAlD
Fluticasone Propionate—NR3C1—vagina—urinary bladder cancer	0.000902	0.0109	CbGeAlD
Fluticasone Propionate—CYP3A4—female reproductive system—urinary bladder cancer	0.000754	0.00912	CbGeAlD
Fluticasone Propionate—NR3C1—lymph node—urinary bladder cancer	0.000583	0.00705	CbGeAlD
Fluticasone Propionate—Malaise—Etoposide—urinary bladder cancer	0.000299	0.00128	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000299	0.00128	CcSEcCtD
Fluticasone Propionate—Face oedema—Epirubicin—urinary bladder cancer	0.000298	0.00128	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Thiotepa—urinary bladder cancer	0.000298	0.00128	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Thiotepa—urinary bladder cancer	0.000298	0.00128	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000295	0.00127	CcSEcCtD
Fluticasone Propionate—Oedema—Cisplatin—urinary bladder cancer	0.000295	0.00127	CcSEcCtD
Fluticasone Propionate—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000295	0.00127	CcSEcCtD
Fluticasone Propionate—Infection—Cisplatin—urinary bladder cancer	0.000293	0.00126	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00029	0.00124	CcSEcCtD
Fluticasone Propionate—Cough—Etoposide—urinary bladder cancer	0.000289	0.00124	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000289	0.00124	CcSEcCtD
Fluticasone Propionate—Tachycardia—Cisplatin—urinary bladder cancer	0.000288	0.00124	CcSEcCtD
Fluticasone Propionate—Skin disorder—Cisplatin—urinary bladder cancer	0.000287	0.00123	CcSEcCtD
Fluticasone Propionate—Hypertension—Etoposide—urinary bladder cancer	0.000286	0.00123	CcSEcCtD
Fluticasone Propionate—Asthma—Methotrexate—urinary bladder cancer	0.000285	0.00122	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000284	0.00122	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000282	0.00121	CcSEcCtD
Fluticasone Propionate—Chest pain—Etoposide—urinary bladder cancer	0.000282	0.00121	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.00028	0.0012	CcSEcCtD
Fluticasone Propionate—Discomfort—Etoposide—urinary bladder cancer	0.000279	0.0012	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000278	0.00119	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000277	0.00119	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000276	0.00118	CcSEcCtD
Fluticasone Propionate—Face oedema—Doxorubicin—urinary bladder cancer	0.000276	0.00118	CcSEcCtD
Fluticasone Propionate—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000273	0.00117	CcSEcCtD
Fluticasone Propionate—Pain—Gemcitabine—urinary bladder cancer	0.000271	0.00116	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000271	0.00116	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000269	0.00115	CcSEcCtD
Fluticasone Propionate—Infection—Etoposide—urinary bladder cancer	0.000269	0.00115	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Epirubicin—urinary bladder cancer	0.000268	0.00115	CcSEcCtD
Fluticasone Propionate—Asthma—Epirubicin—urinary bladder cancer	0.000267	0.00114	CcSEcCtD
Fluticasone Propionate—Pruritus—Thiotepa—urinary bladder cancer	0.000266	0.00114	CcSEcCtD
Fluticasone Propionate—Pain—Fluorouracil—urinary bladder cancer	0.000266	0.00114	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000265	0.00114	CcSEcCtD
Fluticasone Propionate—Tachycardia—Etoposide—urinary bladder cancer	0.000264	0.00113	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Cisplatin—urinary bladder cancer	0.000263	0.00113	CcSEcCtD
Fluticasone Propionate—Skin disorder—Etoposide—urinary bladder cancer	0.000263	0.00113	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000261	0.00112	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Thiotepa—urinary bladder cancer	0.000258	0.00111	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000257	0.0011	CcSEcCtD
Fluticasone Propionate—Bronchitis—Epirubicin—urinary bladder cancer	0.000256	0.0011	CcSEcCtD
Fluticasone Propionate—Pneumonia—Methotrexate—urinary bladder cancer	0.000256	0.0011	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000255	0.0011	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Methotrexate—urinary bladder cancer	0.000254	0.00109	CcSEcCtD
Fluticasone Propionate—Infestation—Methotrexate—urinary bladder cancer	0.000254	0.00109	CcSEcCtD
Fluticasone Propionate—Pain—Cisplatin—urinary bladder cancer	0.000253	0.00108	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Gemcitabine—urinary bladder cancer	0.00025	0.00107	CcSEcCtD
Fluticasone Propionate—Dizziness—Thiotepa—urinary bladder cancer	0.000249	0.00107	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000248	0.00107	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000248	0.00106	CcSEcCtD
Fluticasone Propionate—Urticaria—Fluorouracil—urinary bladder cancer	0.000247	0.00106	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Methotrexate—urinary bladder cancer	0.000247	0.00106	CcSEcCtD
Fluticasone Propionate—Asthma—Doxorubicin—urinary bladder cancer	0.000247	0.00106	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000246	0.00106	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000243	0.00104	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Etoposide—urinary bladder cancer	0.000241	0.00103	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000241	0.00103	CcSEcCtD
Fluticasone Propionate—Epistaxis—Methotrexate—urinary bladder cancer	0.00024	0.00103	CcSEcCtD
Fluticasone Propionate—Vomiting—Thiotepa—urinary bladder cancer	0.000239	0.00103	CcSEcCtD
Fluticasone Propionate—Pneumonia—Epirubicin—urinary bladder cancer	0.000239	0.00103	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Epirubicin—urinary bladder cancer	0.000238	0.00102	CcSEcCtD
Fluticasone Propionate—Infestation—Epirubicin—urinary bladder cancer	0.000238	0.00102	CcSEcCtD
Fluticasone Propionate—Rash—Thiotepa—urinary bladder cancer	0.000237	0.00102	CcSEcCtD
Fluticasone Propionate—Bronchitis—Doxorubicin—urinary bladder cancer	0.000237	0.00102	CcSEcCtD
Fluticasone Propionate—Dermatitis—Thiotepa—urinary bladder cancer	0.000237	0.00102	CcSEcCtD
Fluticasone Propionate—Headache—Thiotepa—urinary bladder cancer	0.000236	0.00101	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Cisplatin—urinary bladder cancer	0.000233	0.001	CcSEcCtD
Fluticasone Propionate—Pain—Etoposide—urinary bladder cancer	0.000231	0.000993	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000231	0.000992	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000229	0.000985	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000229	0.000984	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Methotrexate—urinary bladder cancer	0.000226	0.000971	CcSEcCtD
Fluticasone Propionate—Epistaxis—Epirubicin—urinary bladder cancer	0.000224	0.000962	CcSEcCtD
Fluticasone Propionate—Pruritus—Gemcitabine—urinary bladder cancer	0.000224	0.000962	CcSEcCtD
Fluticasone Propionate—Nausea—Thiotepa—urinary bladder cancer	0.000224	0.00096	CcSEcCtD
Fluticasone Propionate—Sinusitis—Epirubicin—urinary bladder cancer	0.000223	0.000957	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Etoposide—urinary bladder cancer	0.000223	0.000957	CcSEcCtD
Fluticasone Propionate—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000223	0.000955	CcSEcCtD
Fluticasone Propionate—Pneumonia—Doxorubicin—urinary bladder cancer	0.000221	0.000949	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000221	0.000949	CcSEcCtD
Fluticasone Propionate—Pruritus—Fluorouracil—urinary bladder cancer	0.00022	0.000946	CcSEcCtD
Fluticasone Propionate—Infestation—Doxorubicin—urinary bladder cancer	0.00022	0.000944	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Doxorubicin—urinary bladder cancer	0.00022	0.000944	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000218	0.000934	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000217	0.00093	CcSEcCtD
Fluticasone Propionate—Urticaria—Etoposide—urinary bladder cancer	0.000215	0.000922	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Etoposide—urinary bladder cancer	0.000214	0.000918	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Etoposide—urinary bladder cancer	0.000214	0.000918	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000214	0.000918	CcSEcCtD
Fluticasone Propionate—Eye disorder—Methotrexate—urinary bladder cancer	0.000213	0.000915	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000213	0.000915	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000212	0.000911	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Epirubicin—urinary bladder cancer	0.000212	0.000909	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000212	0.000908	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00021	0.0009	CcSEcCtD
Fluticasone Propionate—Epistaxis—Doxorubicin—urinary bladder cancer	0.000207	0.00089	CcSEcCtD
Fluticasone Propionate—Sinusitis—Doxorubicin—urinary bladder cancer	0.000206	0.000886	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000206	0.000884	CcSEcCtD
Fluticasone Propionate—Dizziness—Fluorouracil—urinary bladder cancer	0.000206	0.000884	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000206	0.000882	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000202	0.000867	CcSEcCtD
Fluticasone Propionate—Vomiting—Gemcitabine—urinary bladder cancer	0.000201	0.000864	CcSEcCtD
Fluticasone Propionate—Mental disorder—Methotrexate—urinary bladder cancer	0.0002	0.000857	CcSEcCtD
Fluticasone Propionate—Rash—Gemcitabine—urinary bladder cancer	0.0002	0.000857	CcSEcCtD
Fluticasone Propionate—Dermatitis—Gemcitabine—urinary bladder cancer	0.0002	0.000856	CcSEcCtD
Fluticasone Propionate—Eye disorder—Epirubicin—urinary bladder cancer	0.000199	0.000856	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Etoposide—urinary bladder cancer	0.000199	0.000855	CcSEcCtD
Fluticasone Propionate—Malnutrition—Methotrexate—urinary bladder cancer	0.000199	0.000852	CcSEcCtD
Fluticasone Propionate—Erythema—Methotrexate—urinary bladder cancer	0.000199	0.000852	CcSEcCtD
Fluticasone Propionate—Headache—Gemcitabine—urinary bladder cancer	0.000198	0.000852	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000198	0.00085	CcSEcCtD
Fluticasone Propionate—Vomiting—Fluorouracil—urinary bladder cancer	0.000198	0.00085	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000196	0.000843	CcSEcCtD
Fluticasone Propionate—Rash—Fluorouracil—urinary bladder cancer	0.000196	0.000843	CcSEcCtD
Fluticasone Propionate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000196	0.000842	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000196	0.000841	CcSEcCtD
Fluticasone Propionate—Headache—Fluorouracil—urinary bladder cancer	0.000195	0.000837	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000194	0.000833	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000193	0.000827	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000192	0.000825	CcSEcCtD
Fluticasone Propionate—Pruritus—Etoposide—urinary bladder cancer	0.000191	0.000821	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Epirubicin—urinary bladder cancer	0.000191	0.000818	CcSEcCtD
Fluticasone Propionate—Nausea—Gemcitabine—urinary bladder cancer	0.000188	0.000807	CcSEcCtD
Fluticasone Propionate—Vomiting—Cisplatin—urinary bladder cancer	0.000188	0.000806	CcSEcCtD
Fluticasone Propionate—Vision blurred—Methotrexate—urinary bladder cancer	0.000187	0.000803	CcSEcCtD
Fluticasone Propionate—Mental disorder—Epirubicin—urinary bladder cancer	0.000187	0.000802	CcSEcCtD
Fluticasone Propionate—Rash—Cisplatin—urinary bladder cancer	0.000186	0.000799	CcSEcCtD
Fluticasone Propionate—Dermatitis—Cisplatin—urinary bladder cancer	0.000186	0.000798	CcSEcCtD
Fluticasone Propionate—Erythema—Epirubicin—urinary bladder cancer	0.000186	0.000797	CcSEcCtD
Fluticasone Propionate—Malnutrition—Epirubicin—urinary bladder cancer	0.000186	0.000797	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Etoposide—urinary bladder cancer	0.000185	0.000794	CcSEcCtD
Fluticasone Propionate—Nausea—Fluorouracil—urinary bladder cancer	0.000185	0.000794	CcSEcCtD
Fluticasone Propionate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000185	0.000792	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000184	0.00079	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000183	0.000786	CcSEcCtD
Fluticasone Propionate—Malaise—Methotrexate—urinary bladder cancer	0.000179	0.000768	CcSEcCtD
Fluticasone Propionate—Dizziness—Etoposide—urinary bladder cancer	0.000179	0.000768	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000179	0.000767	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000765	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000178	0.000764	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000176	0.000757	CcSEcCtD
Fluticasone Propionate—Nausea—Cisplatin—urinary bladder cancer	0.000175	0.000753	CcSEcCtD
Fluticasone Propionate—Vision blurred—Epirubicin—urinary bladder cancer	0.000175	0.000751	CcSEcCtD
Fluticasone Propionate—Cough—Methotrexate—urinary bladder cancer	0.000173	0.000743	CcSEcCtD
Fluticasone Propionate—Mental disorder—Doxorubicin—urinary bladder cancer	0.000173	0.000742	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000172	0.00074	CcSEcCtD
Fluticasone Propionate—Vomiting—Etoposide—urinary bladder cancer	0.000172	0.000738	CcSEcCtD
Fluticasone Propionate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000172	0.000738	CcSEcCtD
Fluticasone Propionate—Erythema—Doxorubicin—urinary bladder cancer	0.000172	0.000738	CcSEcCtD
Fluticasone Propionate—Agitation—Epirubicin—urinary bladder cancer	0.000171	0.000733	CcSEcCtD
Fluticasone Propionate—Rash—Etoposide—urinary bladder cancer	0.000171	0.000732	CcSEcCtD
Fluticasone Propionate—Dermatitis—Etoposide—urinary bladder cancer	0.00017	0.000731	CcSEcCtD
Fluticasone Propionate—Headache—Etoposide—urinary bladder cancer	0.000169	0.000727	CcSEcCtD
Fluticasone Propionate—Chest pain—Methotrexate—urinary bladder cancer	0.000169	0.000725	CcSEcCtD
Fluticasone Propionate—Arthralgia—Methotrexate—urinary bladder cancer	0.000169	0.000725	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000168	0.00072	CcSEcCtD
Fluticasone Propionate—Malaise—Epirubicin—urinary bladder cancer	0.000168	0.000719	CcSEcCtD
Fluticasone Propionate—Discomfort—Methotrexate—urinary bladder cancer	0.000167	0.000717	CcSEcCtD
Fluticasone Propionate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000165	0.000709	CcSEcCtD
Fluticasone Propionate—Palpitations—Epirubicin—urinary bladder cancer	0.000164	0.000705	CcSEcCtD
Fluticasone Propionate—Cough—Epirubicin—urinary bladder cancer	0.000162	0.000696	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000162	0.000695	CcSEcCtD
Fluticasone Propionate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000162	0.000695	CcSEcCtD
Fluticasone Propionate—Infection—Methotrexate—urinary bladder cancer	0.000161	0.000691	CcSEcCtD
Fluticasone Propionate—Nausea—Etoposide—urinary bladder cancer	0.000161	0.00069	CcSEcCtD
Fluticasone Propionate—Hypertension—Epirubicin—urinary bladder cancer	0.00016	0.000688	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00016	0.000684	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000159	0.000682	CcSEcCtD
Fluticasone Propionate—Chest pain—Epirubicin—urinary bladder cancer	0.000158	0.000679	CcSEcCtD
Fluticasone Propionate—Arthralgia—Epirubicin—urinary bladder cancer	0.000158	0.000679	CcSEcCtD
Fluticasone Propionate—Agitation—Doxorubicin—urinary bladder cancer	0.000158	0.000678	CcSEcCtD
Fluticasone Propionate—Anxiety—Epirubicin—urinary bladder cancer	0.000158	0.000676	CcSEcCtD
Fluticasone Propionate—Skin disorder—Methotrexate—urinary bladder cancer	0.000157	0.000675	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000157	0.000674	CcSEcCtD
Fluticasone Propionate—Discomfort—Epirubicin—urinary bladder cancer	0.000156	0.000671	CcSEcCtD
Fluticasone Propionate—Malaise—Doxorubicin—urinary bladder cancer	0.000155	0.000665	CcSEcCtD
Fluticasone Propionate—Dry mouth—Epirubicin—urinary bladder cancer	0.000155	0.000664	CcSEcCtD
Fluticasone Propionate—Palpitations—Doxorubicin—urinary bladder cancer	0.000152	0.000652	CcSEcCtD
Fluticasone Propionate—Oedema—Epirubicin—urinary bladder cancer	0.000152	0.000651	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000152	0.000651	CcSEcCtD
Fluticasone Propionate—Infection—Epirubicin—urinary bladder cancer	0.000151	0.000646	CcSEcCtD
Fluticasone Propionate—Cough—Doxorubicin—urinary bladder cancer	0.00015	0.000644	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000149	0.000638	CcSEcCtD
Fluticasone Propionate—Hypertension—Doxorubicin—urinary bladder cancer	0.000148	0.000637	CcSEcCtD
Fluticasone Propionate—Tachycardia—Epirubicin—urinary bladder cancer	0.000148	0.000635	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000148	0.000633	CcSEcCtD
Fluticasone Propionate—Skin disorder—Epirubicin—urinary bladder cancer	0.000147	0.000632	CcSEcCtD
Fluticasone Propionate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000146	0.000628	CcSEcCtD
Fluticasone Propionate—Chest pain—Doxorubicin—urinary bladder cancer	0.000146	0.000628	CcSEcCtD
Fluticasone Propionate—Anxiety—Doxorubicin—urinary bladder cancer	0.000146	0.000626	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000145	0.000624	CcSEcCtD
Fluticasone Propionate—Discomfort—Doxorubicin—urinary bladder cancer	0.000145	0.000621	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Methotrexate—urinary bladder cancer	0.000144	0.00062	CcSEcCtD
Fluticasone Propionate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000143	0.000614	CcSEcCtD
Fluticasone Propionate—Oedema—Doxorubicin—urinary bladder cancer	0.00014	0.000602	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.00014	0.000602	CcSEcCtD
Fluticasone Propionate—Infection—Doxorubicin—urinary bladder cancer	0.000139	0.000598	CcSEcCtD
Fluticasone Propionate—Pain—Methotrexate—urinary bladder cancer	0.000139	0.000595	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000138	0.000593	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000138	0.00059	CcSEcCtD
Fluticasone Propionate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000137	0.000588	CcSEcCtD
Fluticasone Propionate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000136	0.000585	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000135	0.00058	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000134	0.000573	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000132	0.000569	CcSEcCtD
Fluticasone Propionate—Pain—Epirubicin—urinary bladder cancer	0.00013	0.000556	CcSEcCtD
Fluticasone Propionate—Urticaria—Methotrexate—urinary bladder cancer	0.000129	0.000552	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000128	0.00055	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000128	0.00055	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000128	0.000549	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000125	0.000537	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000125	0.000536	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000124	0.000532	CcSEcCtD
Fluticasone Propionate—Urticaria—Epirubicin—urinary bladder cancer	0.00012	0.000517	CcSEcCtD
Fluticasone Propionate—Pain—Doxorubicin—urinary bladder cancer	0.00012	0.000515	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Epirubicin—urinary bladder cancer	0.00012	0.000514	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Epirubicin—urinary bladder cancer	0.00012	0.000514	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000119	0.000512	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000116	0.000496	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000115	0.000492	CcSEcCtD
Fluticasone Propionate—Pruritus—Methotrexate—urinary bladder cancer	0.000115	0.000492	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000113	0.0011	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000113	0.0011	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—MYC—urinary bladder cancer	0.000113	0.00109	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000113	0.00109	CbGpPWpGaD
Fluticasone Propionate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000112	0.000479	CcSEcCtD
Fluticasone Propionate—Urticaria—Doxorubicin—urinary bladder cancer	0.000111	0.000478	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Metabolism—CYP4B1—urinary bladder cancer	0.000111	0.00108	CbGpPWpGaD
Fluticasone Propionate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000111	0.000476	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000111	0.000476	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000111	0.000476	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000111	0.00108	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—KRAS—urinary bladder cancer	0.000109	0.00106	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	0.000109	0.00106	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000108	0.00104	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Epirubicin—urinary bladder cancer	0.000107	0.00046	CcSEcCtD
Fluticasone Propionate—Dizziness—Methotrexate—urinary bladder cancer	0.000107	0.00046	CcSEcCtD
Fluticasone Propionate—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000106	0.00103	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IFNA2—urinary bladder cancer	0.000106	0.00103	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—SLC19A1—urinary bladder cancer	0.000105	0.00102	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—TP53—urinary bladder cancer	0.000104	0.00101	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—KRAS—urinary bladder cancer	0.000104	0.00101	CbGpPWpGaD
Fluticasone Propionate—Diarrhoea—Epirubicin—urinary bladder cancer	0.000104	0.000445	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000103	0.000444	CcSEcCtD
Fluticasone Propionate—Vomiting—Methotrexate—urinary bladder cancer	0.000103	0.000442	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Metabolism—PRSS3—urinary bladder cancer	0.000102	0.000993	CbGpPWpGaD
Fluticasone Propionate—Rash—Methotrexate—urinary bladder cancer	0.000102	0.000438	CcSEcCtD
Fluticasone Propionate—Dermatitis—Methotrexate—urinary bladder cancer	0.000102	0.000438	CcSEcCtD
Fluticasone Propionate—Headache—Methotrexate—urinary bladder cancer	0.000102	0.000436	CcSEcCtD
Fluticasone Propionate—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000101	0.000984	CbGpPWpGaD
Fluticasone Propionate—Dizziness—Epirubicin—urinary bladder cancer	0.0001	0.00043	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.0001	0.000972	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.0001	0.00097	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HDAC4—urinary bladder cancer	0.0001	0.00097	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTZ1—urinary bladder cancer	9.93e-05	0.000964	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Doxorubicin—urinary bladder cancer	9.93e-05	0.000426	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	9.69e-05	0.00094	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	9.67e-05	0.000938	CbGpPWpGaD
Fluticasone Propionate—Vomiting—Epirubicin—urinary bladder cancer	9.64e-05	0.000414	CcSEcCtD
Fluticasone Propionate—Nausea—Methotrexate—urinary bladder cancer	9.62e-05	0.000413	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Doxorubicin—urinary bladder cancer	9.6e-05	0.000412	CcSEcCtD
Fluticasone Propionate—Rash—Epirubicin—urinary bladder cancer	9.56e-05	0.00041	CcSEcCtD
Fluticasone Propionate—Dermatitis—Epirubicin—urinary bladder cancer	9.55e-05	0.00041	CcSEcCtD
Fluticasone Propionate—Headache—Epirubicin—urinary bladder cancer	9.5e-05	0.000408	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—NCOR1—urinary bladder cancer	9.45e-05	0.000917	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NAT1—urinary bladder cancer	9.42e-05	0.000914	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTO2—urinary bladder cancer	9.42e-05	0.000914	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—ESR1—urinary bladder cancer	9.39e-05	0.000911	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—CDKN1A—urinary bladder cancer	9.33e-05	0.000905	CbGpPWpGaD
Fluticasone Propionate—Dizziness—Doxorubicin—urinary bladder cancer	9.28e-05	0.000398	CcSEcCtD
Fluticasone Propionate—PGR—Signaling by ERBB4—HRAS—urinary bladder cancer	9.27e-05	0.0009	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	9.22e-05	0.000894	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—TP53—urinary bladder cancer	9.18e-05	0.000891	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	9.14e-05	0.000887	CbGpPWpGaD
Fluticasone Propionate—Nausea—Epirubicin—urinary bladder cancer	9.01e-05	0.000387	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	8.96e-05	0.00087	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—ESR2—urinary bladder cancer	8.95e-05	0.000868	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	8.94e-05	0.000868	CbGpPWpGaD
Fluticasone Propionate—Vomiting—Doxorubicin—urinary bladder cancer	8.92e-05	0.000383	CcSEcCtD
Fluticasone Propionate—NR3C2—Gene Expression—ERCC2—urinary bladder cancer	8.89e-05	0.000862	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—HRAS—urinary bladder cancer	8.86e-05	0.000859	CbGpPWpGaD
Fluticasone Propionate—Rash—Doxorubicin—urinary bladder cancer	8.85e-05	0.00038	CcSEcCtD
Fluticasone Propionate—Dermatitis—Doxorubicin—urinary bladder cancer	8.84e-05	0.000379	CcSEcCtD
Fluticasone Propionate—Headache—Doxorubicin—urinary bladder cancer	8.79e-05	0.000377	CcSEcCtD
Fluticasone Propionate—CYP3A7—Metabolism—UGT2B7—urinary bladder cancer	8.61e-05	0.000836	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—PPARG—urinary bladder cancer	8.57e-05	0.000831	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—SMC1A—urinary bladder cancer	8.55e-05	0.00083	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GLI1—urinary bladder cancer	8.38e-05	0.000813	CbGpPWpGaD
Fluticasone Propionate—Nausea—Doxorubicin—urinary bladder cancer	8.33e-05	0.000358	CcSEcCtD
Fluticasone Propionate—PGR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	8.23e-05	0.000799	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	8.21e-05	0.000797	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—TYMP—urinary bladder cancer	8.19e-05	0.000794	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HDAC4—urinary bladder cancer	8.17e-05	0.000792	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.1e-05	0.000786	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	8.03e-05	0.000779	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Generic Transcription Pathway—MYC—urinary bladder cancer	8.02e-05	0.000778	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	7.98e-05	0.000774	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.86e-05	0.000763	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	7.86e-05	0.000763	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	7.86e-05	0.000762	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	7.75e-05	0.000752	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	7.67e-05	0.000744	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—PLAU—urinary bladder cancer	7.53e-05	0.00073	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	7.48e-05	0.000726	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—ESR2—urinary bladder cancer	7.46e-05	0.000723	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—ESR1—urinary bladder cancer	7.42e-05	0.00072	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	7.42e-05	0.00072	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—NAT2—urinary bladder cancer	7.4e-05	0.000718	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	7.32e-05	0.00071	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—TNF—urinary bladder cancer	7.2e-05	0.000699	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	7.18e-05	0.000697	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	7.14e-05	0.000692	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—NCOR1—urinary bladder cancer	6.91e-05	0.00067	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GLI1—urinary bladder cancer	6.85e-05	0.000664	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	6.81e-05	0.00066	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NAT1—urinary bladder cancer	6.81e-05	0.00066	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—PPARG—urinary bladder cancer	6.77e-05	0.000657	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	6.6e-05	0.00064	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—CREBBP—urinary bladder cancer	6.51e-05	0.000631	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—RRM2—urinary bladder cancer	6.39e-05	0.00062	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.23e-05	0.000604	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	6.23e-05	0.000604	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—CREBBP—urinary bladder cancer	6.21e-05	0.000602	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IGF1—urinary bladder cancer	6.13e-05	0.000595	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—HPGDS—urinary bladder cancer	5.92e-05	0.000574	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ENO2—urinary bladder cancer	5.92e-05	0.000574	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.88e-05	0.000571	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—NCOR1—urinary bladder cancer	5.76e-05	0.000558	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—RBX1—urinary bladder cancer	5.74e-05	0.000557	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GSTT1—urinary bladder cancer	5.74e-05	0.000557	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—TYMP—urinary bladder cancer	5.7e-05	0.000553	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.65e-05	0.000548	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—RHOA—urinary bladder cancer	5.62e-05	0.000545	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	5.61e-05	0.000544	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.45e-05	0.000529	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—ESR1—urinary bladder cancer	5.43e-05	0.000527	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—ERCC2—urinary bladder cancer	5.41e-05	0.000525	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TSC1—urinary bladder cancer	5.4e-05	0.000524	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.37e-05	0.000521	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	5.29e-05	0.000514	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NAT2—urinary bladder cancer	5.16e-05	0.000501	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	5.16e-05	0.0005	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—JAG1—urinary bladder cancer	5.14e-05	0.000499	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.01e-05	0.000486	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—PPARG—urinary bladder cancer	4.95e-05	0.00048	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—SMC1A—urinary bladder cancer	4.94e-05	0.00048	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.94e-05	0.000479	CbGpPWpGaD
Fluticasone Propionate—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	4.88e-05	0.000474	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—NQO1—urinary bladder cancer	4.77e-05	0.000463	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—CREBBP—urinary bladder cancer	4.76e-05	0.000462	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—IL2—urinary bladder cancer	4.71e-05	0.000457	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—RBX1—urinary bladder cancer	4.69e-05	0.000455	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.63e-05	0.000449	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—ESR1—urinary bladder cancer	4.52e-05	0.000439	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—RRM2—urinary bladder cancer	4.45e-05	0.000432	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TSC1—urinary bladder cancer	4.41e-05	0.000428	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ESR2—urinary bladder cancer	4.31e-05	0.000418	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—EP300—urinary bladder cancer	4.23e-05	0.00041	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—JAG1—urinary bladder cancer	4.2e-05	0.000407	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—S100B—urinary bladder cancer	4.16e-05	0.000404	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—PPARG—urinary bladder cancer	4.13e-05	0.0004	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	4.12e-05	0.0004	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ENO2—urinary bladder cancer	4.12e-05	0.0004	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—TYMP—urinary bladder cancer	4.12e-05	0.0004	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—SRC—urinary bladder cancer	4.11e-05	0.000399	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	4.04e-05	0.000392	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	4e-05	0.000388	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GSTP1—urinary bladder cancer	3.98e-05	0.000386	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—CREBBP—urinary bladder cancer	3.96e-05	0.000384	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—MYC—urinary bladder cancer	3.86e-05	0.000375	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.85e-05	0.000373	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	3.74e-05	0.000363	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.73e-05	0.000362	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—TYMS—urinary bladder cancer	3.7e-05	0.000359	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GSTM1—urinary bladder cancer	3.66e-05	0.000355	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—NCOR1—urinary bladder cancer	3.66e-05	0.000355	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—GPX1—urinary bladder cancer	3.5e-05	0.00034	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ERCC2—urinary bladder cancer	3.44e-05	0.000334	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—KRAS—urinary bladder cancer	3.4e-05	0.00033	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—S100B—urinary bladder cancer	3.4e-05	0.00033	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.34e-05	0.000324	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—NCOR1—urinary bladder cancer	3.33e-05	0.000323	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NQO1—urinary bladder cancer	3.32e-05	0.000323	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TERT—urinary bladder cancer	3.3e-05	0.00032	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—MTHFR—urinary bladder cancer	3.23e-05	0.000314	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—RHOA—urinary bladder cancer	3.22e-05	0.000313	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—RRM2—urinary bladder cancer	3.22e-05	0.000312	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.16e-05	0.000307	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.16e-05	0.000307	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ERCC2—urinary bladder cancer	3.13e-05	0.000304	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—NCOR1—urinary bladder cancer	3.06e-05	0.000297	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	3.03e-05	0.000294	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TP53—urinary bladder cancer	3.03e-05	0.000294	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.98e-05	0.000289	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.98e-05	0.000289	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ESR1—urinary bladder cancer	2.94e-05	0.000285	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.89e-05	0.000281	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—HRAS—urinary bladder cancer	2.89e-05	0.000281	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.89e-05	0.000281	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—CXCL8—urinary bladder cancer	2.83e-05	0.000275	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Generic Transcription Pathway—MYC—urinary bladder cancer	2.82e-05	0.000274	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	2.77e-05	0.000269	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL2—urinary bladder cancer	2.7e-05	0.000262	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TERT—urinary bladder cancer	2.69e-05	0.000261	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PPARG—urinary bladder cancer	2.62e-05	0.000254	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ESR1—urinary bladder cancer	2.61e-05	0.000254	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.61e-05	0.000253	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—TYMS—urinary bladder cancer	2.58e-05	0.00025	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	2.58e-05	0.00025	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	2.55e-05	0.000247	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	2.55e-05	0.000247	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IGF1—urinary bladder cancer	2.54e-05	0.000247	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—CREBBP—urinary bladder cancer	2.52e-05	0.000244	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—FGFR3—urinary bladder cancer	2.47e-05	0.00024	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.46e-05	0.000239	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—GPX1—urinary bladder cancer	2.44e-05	0.000237	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.4e-05	0.000233	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ESR1—urinary bladder cancer	2.4e-05	0.000233	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.4e-05	0.000233	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	2.4e-05	0.000232	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—PPARG—urinary bladder cancer	2.38e-05	0.000231	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—MYC—urinary bladder cancer	2.35e-05	0.000228	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—RHOA—urinary bladder cancer	2.33e-05	0.000226	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—CREBBP—urinary bladder cancer	2.29e-05	0.000222	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	2.25e-05	0.000218	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	2.16e-05	0.000209	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CREBBP—urinary bladder cancer	2.1e-05	0.000204	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IGF1—urinary bladder cancer	2.08e-05	0.000202	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—EGFR—urinary bladder cancer	2.07e-05	0.000201	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PTGS2—urinary bladder cancer	2.06e-05	0.0002	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	2.05e-05	0.000199	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2e-05	0.000194	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL2—urinary bladder cancer	1.96e-05	0.00019	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—KRAS—urinary bladder cancer	1.95e-05	0.00019	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.92e-05	0.000186	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CCND1—urinary bladder cancer	1.91e-05	0.000185	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—RHOA—urinary bladder cancer	1.9e-05	0.000185	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.86e-05	0.000181	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MMP9—urinary bladder cancer	1.85e-05	0.00018	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	0.000179	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.84e-05	0.000179	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.84e-05	0.000179	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PTEN—urinary bladder cancer	1.84e-05	0.000179	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PPARG—urinary bladder cancer	1.83e-05	0.000177	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PTEN—urinary bladder cancer	1.8e-05	0.000174	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.76e-05	0.000171	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—ERBB2—urinary bladder cancer	1.76e-05	0.000171	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EP300—urinary bladder cancer	1.75e-05	0.00017	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	1.75e-05	0.00017	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.73e-05	0.000168	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.73e-05	0.000168	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—EP300—urinary bladder cancer	1.71e-05	0.000166	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SRC—urinary bladder cancer	1.71e-05	0.000166	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CXCL8—urinary bladder cancer	1.67e-05	0.000162	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—HRAS—urinary bladder cancer	1.66e-05	0.000161	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.63e-05	0.000158	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL2—urinary bladder cancer	1.6e-05	0.000155	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CCND1—urinary bladder cancer	1.56e-05	0.000151	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.53e-05	0.000148	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MMP9—urinary bladder cancer	1.51e-05	0.000147	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.51e-05	0.000146	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PTEN—urinary bladder cancer	1.5e-05	0.000146	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.5e-05	0.000145	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.5e-05	0.000145	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.44e-05	0.000139	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EP300—urinary bladder cancer	1.43e-05	0.000139	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	0.000137	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SRC—urinary bladder cancer	1.39e-05	0.000135	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.39e-05	0.000134	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.39e-05	0.000134	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—MYC—urinary bladder cancer	1.36e-05	0.000132	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.34e-05	0.00013	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.32e-05	0.000128	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.27e-05	0.000123	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TP53—urinary bladder cancer	1.26e-05	0.000122	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.25e-05	0.000122	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MYC—urinary bladder cancer	1.25e-05	0.000121	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—EGFR—urinary bladder cancer	1.22e-05	0.000119	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	0.000117	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.19e-05	0.000116	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KRAS—urinary bladder cancer	1.15e-05	0.000112	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.12e-05	0.000108	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	0.000101	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TP53—urinary bladder cancer	1.03e-05	9.95e-05	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HRAS—urinary bladder cancer	9.81e-06	9.52e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.32e-06	9.04e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PTEN—urinary bladder cancer	9.06e-06	8.79e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.66e-06	8.4e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—EP300—urinary bladder cancer	8.64e-06	8.38e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.56e-06	8.31e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.56e-06	8.31e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.2e-06	7.96e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.05e-06	7.81e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.57e-06	7.34e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.14e-06	5.95e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.9e-06	5.72e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.83e-06	4.68e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.21e-06	4.08e-05	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.02e-06	3.9e-05	CbGpPWpGaD
